Cormedix (HAM:19KA) Cyclically Adjusted Revenue per Share: €0.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:19KA Cormedix Inc HAM:19KA
46 GF Score
Price €7.20
GF Value €56.02
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix Cyclically Adjusted Revenue per Share?

Cormedix HAM:19KA -1.32% 46 Cyclically Adjusted Revenue per Share is €0.66 as of Mar. 2026. GuruFocus rates HAM:19KA with a GF Score™ of 46/100 and a GF Value™ of €56.02 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cormedix's adjusted revenue per share for the three months ended in Mar. 2026 was €1.185. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cormedix's average Cyclically Adjusted Revenue Growth Rate was 310.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 169.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cormedix was 169.90% per year. The lowest was 0.00% per year. And the median was 29.35% per year.

As of today (2026-07-16), Cormedix's current stock price is €7.202. Cormedix's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.66. Cormedix's Cyclically Adjusted PS Ratio of today is 10.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cormedix was 586.00. The lowest was 9.04. And the median was 161.84.


Cormedix  (HAM:19KA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cormedix's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.202/0.66
=10.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cormedix was 586.00. The lowest was 9.04. And the median was 161.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cormedix Cyclically Adjusted Revenue per Share Related Terms


Cormedix Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cormedix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix Cyclically Adjusted Revenue per Share Chart

Cormedix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.55

Cormedix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.55 0.66

HAM:19KA vs STTK, ACHV, EIKN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Cormedix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cormedix's Cyclically Adjusted PS Ratio falls into.


HAM:19KA
46GF Score
Cormedix Inc HAM:19KA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cormedix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cormedix's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.185/330.2130*330.2130
=1.185

Current CPI (Mar. 2026) = 330.2130.

Cormedix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.002 241.018 0.003
201609 0.005 241.428 0.007
201612 0.014 241.432 0.019
201703 0.005 243.801 0.007
201706 0.012 244.955 0.016
201709 0.004 246.819 0.005
201712 0.006 246.524 0.008
201803 0.001 249.554 0.001
201806 0.000 251.989 0.000
201809 0.017 252.439 0.022
201812 0.001 251.233 0.001
201903 0.006 254.202 0.008
201906 0.001 256.143 0.001
201909 0.002 256.759 0.003
201912 0.001 256.974 0.001
202003 0.003 258.115 0.004
202006 0.001 257.797 0.001
202009 0.003 260.280 0.004
202012 0.001 260.474 0.001
202103 0.002 264.877 0.002
202106 0.000 271.696 0.000
202109 0.001 274.310 0.001
202112 0.001 278.802 0.001
202203 0.000 287.504 0.000
202206 0.001 296.311 0.001
202209 0.000 296.808 0.000
202212 0.001 296.797 0.001
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.013 314.175 0.014
202409 0.175 315.301 0.183
202412 0.484 315.605 0.506
202503 0.524 319.799 0.541
202506 0.479 322.561 0.490
202509 1.030 324.800 1.047
202512 1.166 324.054 1.188
202603 1.185 330.213 1.185

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.66 mean?
Cormedix (HAM:19KA) has a Cyclically Adjusted Revenue per Share of €0.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cormedix and its competitors.
Is Cormedix's Cyclically Adjusted Revenue per Share too high?
Cormedix's current Cyclically Adjusted Revenue per Share is €0.66. Overall, Cormedix has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cormedix's Cyclically Adjusted Revenue per Share compare to STTK and ACHV?
Cormedix's Cyclically Adjusted Revenue per Share of €0.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cormedix and its competitors. Cormedix's current Cyclically Adjusted Revenue per Share is €0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cormedix stock overvalued right now?
Based on GuruFocus' analysis, Cormedix (HAM:19KA) is currently considered Possible Value Trap. The stock's GF Value™ is €56.02, compared to a current price of €7.20 — trading 87.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.66. Cormedix's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cormedix (HAM:19KA), the current Cyclically Adjusted Revenue per Share is €0.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €7.20 is trading 87.1% below its estimated GF Value™ of €56.02. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • Cyclically Adjusted Revenue per Share: €0.66
  • GF Value™: €56.02 vs. price of €7.20 (87.1% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
46GF Score

Get the complete analysis for HAM:19KA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.20
Price
€56.02
GF Value